Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals reports news about its clinical-stage biotechnology business and its strategy to build a neurology and oncology pipeline. Company updates commonly address anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system, including TPI 287 and Berubicin, as well as clinical-data presentations and regulatory-development planning.
Recurring developments also include executive leadership changes, pipeline prioritization, business-development strategy, financial results, capital-allocation commentary, shareholder voting matters, governance updates and capital-structure disclosures tied to its Nasdaq-listed common stock.
CNS Pharmaceuticals (NASDAQ:CNSP) reported second quarter 2026 results and progress on its strategic transformation toward a diversified, high-value pipeline. Cash and cash equivalents were approximately $20.0 million at June 30, 2026, up from $7.2 million at year-end 2025, largely driven by an oversubscribed private placement that generated $22.5 million in gross proceeds ($20.7 million net).
The company believes this cash will fund planned operations beyond the next twelve months as it pursues in-licensing or acquisition of one or more assets by year-end 2026. CNS completed its global Berubicin glioblastoma trial and is closing out the study while engaging in out-licensing discussions for Berubicin and TPI 287. Second-quarter 2026 R&D expenses were $1.2 million, G&A expenses were $1.5 million, and net loss was $2.6 million, or $0.37 per share. A May 2026 financing expanded the shareholder base with biotech-focused institutional investors and the board was strengthened with the appointment of life sciences executive Michal Fisher.
CNS Pharmaceuticals (NASDAQ:CNSP) participated in a Virtual Investor "What This Means" segment where CFO Steve O'Loughlin discussed the Company's recently completed oversubscribed $22.5 million financing. Topics included the strategic reset, acquisition-focused transformation, institutional investor participation, investor reception, balance sheet strength and long-term growth and shareholder value objectives.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q1 2026 results and detailed a strategic transformation toward an acquisition-driven growth model focused on differentiated clinical-stage neurology and oncology assets.
The company closed an oversubscribed $22.5 million private placement after quarter end and is pursuing out-licensing of legacy glioblastoma programs Berubicin and TPI-287. Q1 2026 general and administrative expense was $1.43 million, research and development expense was $3.54 million, and net loss was $4.94 million, all higher year over year. Cash and cash equivalents were $2.95 million on March 31, 2026, excluding the private placement proceeds, which are expected to fund operations beyond twelve months.
CNS Pharmaceuticals (NASDAQ:CNSP) entered securities purchase agreements for an oversubscribed private placement expected to raise approximately $22.5 million before fees, with closing targeted on or about May 5, 2026. Investors include ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners.
The offering comprises 650,000 common shares at $2.30 and 9,143,479 pre-funded warrants at $2.299 (exercise price $0.001). Net proceeds are intended to fund acquisitions of clinical-stage assets, working capital, and general corporate purposes; the company is pursuing out-licensing of legacy glioblastoma programs.
CNS Pharmaceuticals (NASDAQ:CNSP) announced a strategic pivot on March 11, 2026 toward building a high-value pipeline focused on neurology and oncology, led by a newly formed executive team. The company completed a rigorous, data-driven review and plans to pursue acquisitions or in-licensing of preclinical and clinical-stage assets.
CNSP said it will explore out-licensing of legacy assets berubicin and TPI 287 to concentrate resources on differentiated programs with defined value inflection points and unmet medical need.
CNS Pharmaceuticals (NASDAQ:CNSP) appointed Lynne Kelley, MD, FACS as Chief Medical Officer effective March 2, 2026, completing its executive leadership team. Dr. Kelley brings more than two decades of clinical development, translational medicine and global regulatory strategy across oncology, rare diseases, CNS and medical devices.
She has led Phase 1–3 programs, supported INDs, NDAs, BLAs, PMAs and breakthrough/orphan designations, and has prior CMO roles at multiple biotechs and leadership experience at Boston Scientific and Becton Dickinson.
CNS Pharmaceuticals (NASDAQ:CNSP) announced that new President & CEO Rami Levin has recruited three senior executives effective March 2, 2026: Steven O'Loughlin as CFO, Eric Faulkner as CTO and Dylan Wenke as CBO. The hires aim to accelerate a strategic transformation focused on pipeline optimization, disciplined capital allocation and execution.
The company said the team brings decades of biotech operational, clinical and transaction experience and will finalize a comprehensive strategic evaluation with milestone-driven transparency for stakeholders.
CNS Pharmaceuticals (NASDAQ:CNSP) issued a letter from newly appointed President and CEO Rami Levin outlining a strategic evaluation of the company on January 27, 2026. The CEO said the review covers the pipeline, development priorities, operations and capital allocation, with three guiding principles: Patients First, Pipeline Enrichment and Optimization, and Disciplined Value Creation. The company identified TPI 287 as its lead asset and core value driver and plans to refine clinical and regulatory strategies, prioritize indications, align with regulators and raise capital toward data and milestone achievements.
CNS Pharmaceuticals (NASDAQ:CNSP) announced a CEO transition: John Climaco has stepped down and Rami Levin, MBA, will become President & Chief Executive Officer effective January 1, 2026. Levin brings nearly 30 years of global biopharma experience across oncology, neurology, rare diseases, and cell & gene therapy and highlights include scaling organizations, raising capital, and advancing late‑stage programs. The release cites Levin's prior roles at Saniona, ImStem, Sobi, Merck Serono and a record of growing Sobi North American revenue from $46M to >$500M. CNS expects Levin to advance TPI 287 and strengthen commercial and development strategy.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q3 2025 results and a corporate update on November 17, 2025. Key financials: net loss $3.3M vs $5.6M year-ago, R&D $2.2M vs $4.2M, G&A $1.1M vs $1.4M, and cash $9.9M as of September 30, 2025. Management says cash is expected to fund operations into the second half of 2026. Lead program TPI 287 — an abeotaxane engineered for blood-brain barrier penetration — showed Phase 1 activity in GBM with 3 complete responses and 9 partial responses among 23 evaluable patients. The company plans FDA engagement on a potential Phase 2/registration study in early 2026.